Osteosarcoma treatment - where do we stand? A state of the art review.
about
A comparative study between limb-salvage and amputation for treating osteosarcomaAssociation of genetic polymorphisms with osteosarcoma risk: a meta-analysisFarmer to pharmacist: curcumin as an anti-invasive and antimetastatic agent for the treatment of cancerKnockdown of ubiquitin-specific peptidase 39 inhibited the growth of osteosarcoma cells and induced apoptosis in vitro.Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma.Long noncoding RNA ATB promotes osteosarcoma cell proliferation, migration and invasion by suppressing miR-200s.Blocking fatty acid synthase inhibits tumor progression of human osteosarcoma by regulating the human epidermal growth factor receptor 2/phosphoinositide 3-kinase/protein kinase B signaling pathway in xenograft modelsTargeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.Allosteric DNA nanoswitches for controlled release of a molecular cargo triggered by biological inputs.Neoadjuvant chemotherapy combined with limb salvage surgery in patients with limb osteosarcoma of Enneking stage II: a retrospective studyCo-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse modelsIT-based Psychosocial Distress Screening in Patients with Sarcoma and Parental Caregivers via Disease-specific Online Social Media CommunitiesRecurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma.Animal models in osteosarcoma.Development and translational imaging of a TP53 porcine tumorigenesis modelEpigenetic pathways regulating bone homeostasis: potential targeting for intervention of skeletal disorders.Clinical and biological significance of PIM1 kinase in osteosarcoma.Targeting osteosarcoma.Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate.Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma.Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.What sports activity levels are achieved in patients with modular tumor endoprostheses of osteosarcoma about the knee?Analysis of gene expression in cyclooxygenase-2-overexpressed human osteosarcoma cell lines.Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.Role of β-isomerized C-terminal telopeptides (β-CTx) and total procollagen type 1 amino-terminal propeptide (tP1NP) as osteosarcoma biomarkersTime-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcomaCD8(+)/FOXP3(+)-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study.Preclinical mouse models of osteosarcomaEstablishment of a patient-derived orthotopic osteosarcoma mouse modelPrognostic value and in vitro biological relevance of Neuropilin 1 and Neuropilin 2 in osteosarcoma.Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma.Prognostic implications of RB1 tumour suppressor gene alterations in the clinical outcome of human osteosarcoma: a meta-analysis.MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.Clinicopathological and prognostic significance of chemokine receptor CXCR4 in patients with bone and soft tissue sarcoma: a meta-analysis.Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.Arsenic Trioxide Activate Transcription of Heme Oxygenase-1 by Promoting Nuclear Translocation of NFE2L2.Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcomaClinical Epidemiology of Low-Grade and Dedifferentiated Osteosarcoma in Norway during 1975 and 2009.Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis
P2860
Q26753095-54ABA0DA-A1DF-46F4-88EA-29647E47AF9CQ26797065-D7BD3C5F-D682-40C5-A0DF-EBFACD3E96B5Q28649395-5AC127C8-10EE-4E50-A246-5F04BFB99AF5Q33556192-38306B5A-E5DB-4172-8DB6-402B0B311303Q33607479-1B57D077-706B-4BA1-9497-BEC431700035Q33622642-7200FEA6-B3C5-46C8-A178-1B36597FAB14Q33723733-A88CB3B2-6C6F-4AAE-8741-DAF959855476Q33728298-2923CBD3-96C7-407B-9FFF-FF5608F4311CQ33749685-C8D2064D-F618-42C7-AC37-23555630C2D7Q33758207-057A874A-0777-47EC-87D1-B3988906482FQ33761531-B4B5B9B1-7CC4-4A89-BAC0-EC65C400B640Q33770815-256F99C0-DE82-450C-905E-BA024D1FC257Q33850534-696CB984-25AB-4114-B847-5028C08E486BQ33917772-42C159A0-11C9-4417-9472-89104F79F3DDQ34117482-56688DE4-6FCD-4A01-9516-0314AE84A9ECQ34437672-B90217E5-1585-4D9D-BF49-488677E3516CQ34674917-9121C60D-F938-4C71-A7BD-F458D1EC2287Q34792994-C58D209E-5346-4B75-856D-E961B10FA90AQ34990949-44EB5705-421E-482B-95AE-CC6BB4F8E5DCQ34991299-199DD32F-91CE-464F-8307-4A23AE6BC63EQ35007531-623F32A3-7631-49C8-992C-CADA4C25FA4AQ35050319-DC48EC6A-C775-4751-BBE2-587F4AC1F976Q35088724-5A01A08A-610C-42B0-954F-87721658CC0FQ35138344-BA60C0BD-B9B4-4D88-A88A-18C59A75D82CQ35173642-B05BC77E-0789-450A-A0C5-63E3606F2E18Q35190158-FFE0153A-6336-4D23-853A-B753322561CAQ35506606-D91EF2B8-1D59-43C8-9FD0-1783540EBC94Q35575644-A8CA385B-0E66-449B-BCEE-B6FD89613914Q35595609-2AB61183-352B-4330-B4B3-0FDC11D1BCA8Q35663028-2F3C53AC-6196-4AFD-9EFC-781AB982264BQ35815100-D9FFC53B-2920-4445-BAFF-E9944047DC24Q35821807-336DB122-92EB-445D-9F3C-53ACDCA6192DQ35832247-F1AED636-674C-4B49-A218-ECA850688845Q35851832-9A0A19C1-93CE-43CF-809E-648FB06F63DFQ35871574-1EC69E2C-5338-4509-8B39-D2EB1BBEE54BQ35894540-39BBC3E8-8045-454B-8D20-9DCD454C438CQ35942156-CB4D1D2B-6D61-4A47-BA93-ADA04620BFE3Q35958404-389A8258-AB01-4451-BC94-712FAE9F3C84Q36054721-492BF963-6A42-4DF9-A8A1-E6259F77CBEBQ36095051-6299965B-C668-46A3-BDBB-973102AE6C4B
P2860
Osteosarcoma treatment - where do we stand? A state of the art review.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Osteosarcoma treatment - where do we stand? A state of the art review.
@ast
Osteosarcoma treatment - where do we stand? A state of the art review.
@en
Osteosarcoma treatment - where do we stand? A state of the art review.
@nl
type
label
Osteosarcoma treatment - where do we stand? A state of the art review.
@ast
Osteosarcoma treatment - where do we stand? A state of the art review.
@en
Osteosarcoma treatment - where do we stand? A state of the art review.
@nl
prefLabel
Osteosarcoma treatment - where do we stand? A state of the art review.
@ast
Osteosarcoma treatment - where do we stand? A state of the art review.
@en
Osteosarcoma treatment - where do we stand? A state of the art review.
@nl
P2093
P1476
Osteosarcoma treatment - where do we stand? A state of the art review
@en
P2093
Anja Luetke
Heribert Juergens
P304
P356
10.1016/J.CTRV.2013.11.006
P50
P577
2013-11-27T00:00:00Z